Finanzen von Vaxcyte Inc (PCVX)PCVXVaxcyte Inc

Evaluating the bottom line, Vaxcyte, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.51%, provide a clear picture of how effectively PCVX converts its operational activities into shareholder value.

In the context of the broader market, PCVX competes directly with industry leaders such as OGCP and KRYS. With a market capitalization of $9.51B, it holds a leading position in the sector. When comparing efficiency, PCVX's gross margin of N/A stands against OGCP's N/A and KRYS's 94.60%. Such benchmarking helps identify whether Vaxcyte, Inc. is trading at a premium or discount relative to its financial performance.

Vaxcyte has shown a year-over-year stock price increase of 35.58% and a strong current ratio of 5.72, suggesting good liquidity despite ongoing losses.